Article in Cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
40 authors.
Samuel W BradyDepartment of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-5518-7800
Michael A ArnoldDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0002-6921-3720
Mingjuan WangDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-3885-2773
Ramzi AlsallaqDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-2496-9620
Li DongDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-7222-1900
Mohammad Aslam KhanDepartment of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-1855-1279
Wentao YangDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-4783-5908
Kayla L StrattonClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-5201-4565
Wei LiuDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-2447-8792
Yan ChenDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0009-0008-0650-7255
Emily PlylerDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-2642-1674
Jacob A SteeleDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-9924-2226
Brent B PowersDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0009-0001-1070-5659
David RosenfeldDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0009-0000-6986-3451
Michael N EdmonsonDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-0339-700X
Yuan FengDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0009-0007-8932-4405
Nadezhda V TerekhanovaDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-8711-4649
Kohei HagiwaraDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-7787-2008
Sasi ArunachalamDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-5282-9377
Heather L MulderDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-2024-9498
Deo Kumar SrivastavaDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-6693-8120
Michael RuschDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-5363-1848
Vikki G NolanDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-9753-0870
Aaron McDonaldDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-4240-1131
Yadav SapkotaDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-5943-9454
Maria M GramatgesDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-0947-104X
Lucie M TurcotteDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0003-4106-6172
Cindy ImDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0003-0931-9432
Rebecca M HowellDepartment of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0803-071X
John EastonDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-4503-6608
Xiaotu MaDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-6233-2145
Zhaoming WangDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-7556-3869
Wendy M LeisenringClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0001-7405-0906
Miriam ConcesDepartment of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio.ORCID 0000-0002-5646-4299
Joseph P NegliaDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-5525-0598
Yutaka YasuiDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-7717-8638
Smita BhatiaDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama.ORCID 0000-0002-7755-5683
David W EllisonDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-1239-7757
Jinghui ZhangDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-3350-9682
Gregory T ArmstrongDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-8722-4207
Funding
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9M
Mach-LETSGO: Machine-LEarning of Treatment, Survey, and Genetics towards Obtaining Correct Classification of Chronic Conditions in Adult Survivors in the Childhood Cancer Survivor Study - CCSS SupplU24CA055727 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Gregory Armstrong · 1999 to 2026
$96.7M
American Lebanese Syrian Associated Charities (ALSAC)National Cancer Institute (NCI) 3U24CA055727National Cancer Institute (NCI) 3U24CA055727-28S1NCI NIH HHS P30 CA021765NCI NIH HHS U24 CA055727
6 · The paper itself
Abstract
Childhood cancer survivors have a heightened risk of developing subsequent neoplasms (SN) related to therapy. We analyzed whole-genome, exome, and RNA sequencing of 200 breast, meningioma, and thyroid SNs, which developed a median of 26.4 years after childhood cancer, among 160 survivors. Meningioma and thyroid SNs were enriched for driver gene rearrangements compared with de novo tumors, including NF2-disrupting alterations and kinase fusions potentially induced by radiation. Radiation correlated with increased insertion-deletion signature ID5. Nitrogen mustard treatment correlated with elevated "flat" signature SBS5 in breast and meningioma SNs; in vitro, these agents caused an unresolved flat signature associated with multiple flat signatures from the Catalogue of Somatic Mutations in Cancer. In meningioma, platinum therapy correlated with NF2 splice-site variants. Analysis of 19 multisample survivors revealed intrapatient heterogeneity in meningioma, including clonally independent tumors. These results demonstrate the long-term impact of childhood cancer treatment on the genomes of SNs developing in adulthood, which may guide SN treatment and prevention. SIGNIFICANCE: This represents the most comprehensive genomic characterization of SNs from childhood cancer survivors to date, revealing the mutagenic impact of multiple therapies on the SN genome, including the potential impact of nitrogen mustards such as cyclophosphamide. These results may guide the optimization of future cancer treatment regimens to prevent SN development. See related commentary by Bertrums and van Boxtel, p. 1483.
Indexed as
Cancer SurvivorsMutationNeoplasmsNeoplasms, Second PrimaryChildFemaleHumansMeningioma
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer. · full record | OpenQuestion